• T Huo, Y-H Huang, J-C Wu, J-H Chiang, P-C Lee, F-Y Chang, and S-D Lee.
• Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan. tihuo@vghtpe.gov.tw
• Aliment. Pharmacol. Ther. 2004 Jun 15; 19 (12): 1301-8.

BackgroundTransarterial chemoembolization (TACE) and percutaneous acetic acid injection (PAI) are effective loco-regional therapies for hepatocellular carcinoma (HCC).AimTo compare the therapeutic efficacy of TACE vs. PAI for unresectable HCC.MethodsA total of 310 patients with unresectable HCCs (size ResultsThe overall survival was not significantly different between the two groups (P = 0.508). Among 129 patients with large (3.1-6 cm) HCCs, the overall survival was significantly better for the TACE group (P = 0.018). Cox multivariate analysis showed that Child-Pugh B [relative risk (RR): 4.2, 95% confidence interval (CI): 2.3-7.7, P < 0.001] and PAI therapy (RR: 1.4, 95%: 1.0-1.9, P = 0.057) were poor prognostic predictors; the progression-free survival was also significantly better in the TACE group (P = 0.038). Among 181 patients with small (ConclusionsPatients with large HCC undergoing TACE tend to have a more favourable long-term outcome. For small HCC, either TACE or PAI therapy could be recommended as the primary treatment modality.

28 keywords...

hide…